22:52:54 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-29 Kvartalsrapport 2024-Q3
2024-10-15 X-dag halvårsutdelning ORNBV 0.81
2024-10-15 X-dag halvårsutdelning ORNAV 0.81
2024-08-08 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-03-21 X-dag halvårsutdelning ORNBV 0.81
2024-03-21 X-dag halvårsutdelning ORNAV 0.81
2024-03-20 Årsstämma 2024
2024-02-13 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-17 Kvartalsrapport 2023-Q2
2023-04-27 Kvartalsrapport 2023-Q1
2023-03-23 X-dag ordinarie utdelning ORNAV 1.60 EUR
2023-03-23 X-dag ordinarie utdelning ORNBV 1.60 EUR
2023-03-22 Årsstämma 2023
2023-02-09 Bokslutskommuniké 2022
2022-10-20 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-03-24 X-dag ordinarie utdelning ORNAV 1.50 EUR
2022-03-24 X-dag ordinarie utdelning ORNBV 1.50 EUR
2022-03-23 Årsstämma 2022
2022-02-10 Bokslutskommuniké 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-07-19 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-26 X-dag ordinarie utdelning ORNAV 1.50 EUR
2021-03-26 X-dag ordinarie utdelning ORNBV 1.50 EUR
2021-03-25 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-10-21 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-07 X-dag ordinarie utdelning ORNBV 1.50 EUR
2020-05-07 X-dag ordinarie utdelning ORNAV 1.50 EUR
2020-05-06 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-03-26 X-dag ordinarie utdelning ORNBV 1.50 EUR
2020-02-05 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-17 Kvartalsrapport 2019-Q2
2019-04-25 Kvartalsrapport 2019-Q1
2019-03-27 X-dag ordinarie utdelning ORNAV 1.50 EUR
2019-03-27 X-dag ordinarie utdelning ORNBV 1.50 EUR
2019-03-26 Årsstämma 2019
2019-02-06 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-18 Kvartalsrapport 2018-Q2
2018-04-24 Kvartalsrapport 2018-Q1
2018-03-21 X-dag ordinarie utdelning ORNAV 1.45 EUR
2018-03-21 X-dag ordinarie utdelning ORNBV 1.45 EUR
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-07-19 Kvartalsrapport 2017-Q2
2017-05-18 Kapitalmarknadsdag 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-03-23 X-dag ordinarie utdelning ORNAV 1.35 EUR
2017-03-23 X-dag bonusutdelning ORNAV 0.2
2017-03-23 X-dag bonusutdelning ORNBV 0.2
2017-03-23 X-dag ordinarie utdelning ORNBV 1.35 EUR
2017-03-22 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-25 Kvartalsrapport 2016-Q3
2016-07-19 Kvartalsrapport 2016-Q2
2016-04-27 Kvartalsrapport 2016-Q1
2016-03-23 X-dag ordinarie utdelning ORNBV 1.30 EUR
2016-03-23 X-dag ordinarie utdelning ORNAV 1.30 EUR
2016-03-22 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-27 Kvartalsrapport 2015-Q3
2015-07-28 Kvartalsrapport 2015-Q2
2015-05-26 Kapitalmarknadsdag 2015
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-25 X-dag ordinarie utdelning ORNBV 1.30 EUR
2015-03-25 X-dag ordinarie utdelning ORNAV 1.30 EUR
2015-03-24 Årsstämma 2015
2015-02-04 Bokslutskommuniké 2014
2014-10-21 Kvartalsrapport 2014-Q3
2014-07-29 Kvartalsrapport 2014-Q2
2014-04-29 Kvartalsrapport 2014-Q1
2014-03-26 X-dag ordinarie utdelning ORNAV 1.25 EUR
2014-03-26 X-dag ordinarie utdelning ORNBV 1.25 EUR
2014-03-25 Årsstämma 2014
2014-02-04 Bokslutskommuniké 2013
2013-10-22 Kvartalsrapport 2013-Q3
2013-07-30 Kvartalsrapport 2013-Q2
2013-04-23 Kvartalsrapport 2013-Q1
2013-03-20 X-dag ordinarie utdelning ORNAV 1.30 EUR
2013-03-20 X-dag ordinarie utdelning ORNBV 1.30 EUR
2013-03-19 Årsstämma 2013
2013-02-05 Bokslutskommuniké 2012
2012-10-23 Kvartalsrapport 2012-Q3
2012-07-31 Kvartalsrapport 2012-Q2
2012-05-24 Kapitalmarknadsdag 2012
2012-04-24 Kvartalsrapport 2012-Q1
2012-03-21 X-dag ordinarie utdelning ORNAV 1.30 EUR
2012-03-21 X-dag bonusutdelning ORNAV 0.12
2012-03-21 X-dag ordinarie utdelning ORNBV 1.30 EUR
2012-03-21 X-dag bonusutdelning ORNBV 0.12
2012-03-20 Årsstämma 2012
2012-02-07 Bokslutskommuniké 2011
2011-10-25 Kvartalsrapport 2011-Q3
2011-08-02 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-01 X-dag bonusutdelning ORNBV 0.06
2011-04-01 X-dag bonusutdelning ORNAV 0.06
2011-04-01 X-dag ordinarie utdelning ORNAV 1.20 EUR
2011-04-01 X-dag ordinarie utdelning ORNBV 1.20 EUR
2011-03-31 Årsstämma 2011
2011-02-09 Bokslutskommuniké 2010
2010-10-26 Kvartalsrapport 2010-Q3
2010-08-10 Kvartalsrapport 2010-Q2
2010-04-27 Kvartalsrapport 2010-Q1
2010-03-25 X-dag ordinarie utdelning ORNBV 1.00 EUR
2010-03-25 X-dag bonusutdelning ORNBV 0.1
2010-03-25 X-dag bonusutdelning ORNAV 0.1
2010-03-25 X-dag ordinarie utdelning ORNAV 1.00 EUR
2009-03-24 X-dag ordinarie utdelning ORNAV 0.95 EUR
2009-03-24 X-dag ordinarie utdelning ORNBV 0.95 EUR
2008-03-26 X-dag ordinarie utdelning ORNBV 1.00 EUR
2007-04-03 X-dag ordinarie utdelning ORNAV 1.00 EUR
2007-04-03 X-dag ordinarie utdelning ORNBV 1.00 EUR
2006-03-22 X-dag ordinarie utdelning ORNBV 0.85 EUR
2005-03-22 X-dag ordinarie utdelning ORNAV 0.55 EUR
2005-03-22 X-dag ordinarie utdelning ORNBV 0.55 EUR
2004-09-15 X-dag bonusutdelning ORNAV 2.14
2004-09-15 X-dag bonusutdelning ORNBV 2.14
2004-03-23 X-dag ordinarie utdelning ORNAV 1.60 EUR
2004-03-23 X-dag ordinarie utdelning ORNBV 1.60 EUR
2003-12-12 X-dag bonusutdelning ORNAV 1.5
2003-12-12 X-dag bonusutdelning ORNBV 1.5
2003-03-23 X-dag ordinarie utdelning ORNAV 0.93 EUR
2003-03-23 X-dag ordinarie utdelning ORNBV 0.93 EUR
2002-04-16 X-dag ordinarie utdelning ORNBV 1.10 EUR
2002-04-16 X-dag ordinarie utdelning ORNAV 1.10 EUR
2001-03-30 X-dag ordinarie utdelning ORNAV 1.20 EUR
2001-03-30 X-dag ordinarie utdelning ORNBV 1.20 EUR
2000-03-31 X-dag ordinarie utdelning ORNAV 1.18 EUR
2000-03-31 X-dag ordinarie utdelning ORNBV 1.18 EUR
1999-07-28 X-dag bonusutdelning ORNBV 13.46
1999-07-28 X-dag bonusutdelning ORNAV 13.46
1999-04-09 X-dag ordinarie utdelning ORNAV 6.50 EUR
1999-04-09 X-dag ordinarie utdelning ORNBV 6.50 EUR
1998-04-21 X-dag ordinarie utdelning ORNBV 7.50 EUR
1998-04-21 X-dag ordinarie utdelning ORNAV 7.50 EUR
1997-04-22 X-dag ordinarie utdelning ORNAV 5.00 EUR
1997-04-22 X-dag ordinarie utdelning ORNBV 5.00 EUR
1996-04-23 X-dag ordinarie utdelning ORNBV 4.00 EUR
1996-04-23 X-dag ordinarie utdelning ORNAV 4.00 EUR

Beskrivning

LandFinland
ListaLarge Cap Helsinki
SektorHälsovård
IndustriLäkemedel & Handel
Orion är en koncern med verksamhet inom läkemedelsindustrin. Bolaget bedriver forskning och utveckling av humana- och veterinära läkemedel, där störst fokus innehas inom sjukdomar som drabbar nervsystemet, samt onkologi och luftvägssjukdomar. Idag återfinns bolagets produkter på global nivå, med störst närvaro inom Norden och övriga Europa. Bolagets huvudkontor ligger i Esbo.
2022-10-27 07:00:00


PRESS RELEASE                      27 OCTOBER 2022 AT 8.00 a.m. EEST

Orion Research Foundation is awarding EUR 1 million in grants and two EUR 100,000 special grants today

The Board of Directors of the Orion Research Foundation will today award grants on the basis of applications amounting to a total of EUR 1 million for 2023. This year, the Board of the Research Foundation will also award two special grants of EUR 100,000 to mid-career researchers. The grants will be awarded to Associate Professor Tiina Sikanen from the Division of Pharmaceutical Chemistry and Technology at the University of Helsinki, and to Professor of Cancer Biology Jukka Westermarck from the Institute of Biomedicine and
Research Director at the Turku Bioscience Centre at the University of Turku.

Each year, the Orion Research Foundation distributes its investment income and the donation it receives from Orion Corporation as grants to young researchers and researchers who have recently gained doctorates to enable them to continue their research. In recent years, the Foundation has awarded grants by application amounting to a total of approximately EUR 1 million annually to researchers in the fields of medicine, veterinary medicine, pharmacy and related natural sciences such as chemistry and physics. This year, two special awards, which could not be applied for, will also be awarded. The two special grants will be awarded to mid-career researchers both for their valuable research work and for speaking publicly in support of research funding, thus promoting the cause of all researchers.

In the past, the Research Foundation has granted three special awards on the basis of various award criteria to Hannes Lohi, research group leader, in 2012, and to Academy Professor Johanna Ivaska and Professor of Pharmacogenetics Mikko Niemi in 2017.

Seeking a drug that is harmless for humans and the environment

Tiina Sikanen is Associate Professor at the Division of Pharmaceutical Chemistry and Technology at the University of Helsinki. She earned a PhD in pharmacy from the University of Helsinki in 2007 and a Master of Science in Technology degree in chemical engineering from Aalto University in 2010.

Associate Professor Sikanen’s research group develops microchip-based methods for studying the metabolism of pharmaceutical ingredients, in other words, their transformation, in the body using the enzymes of various animal species and humans. Sikanen’s aim is to develop methods that enable rapid and patient-specific metabolite analytics to support personalised treatments. Patient-specific metabolite analytics can reduce the side effects of medicines as well as drug residues that burden the environment.

“I want to form an overall idea of how research can provide a better understanding in the future of the environmental impacts and risks associated with pharmaceuticals ending up in the environment,” Sikanen says. In her appearances and publications, she has improved the public understanding of the environmental risks posed by active pharmaceutical ingredients and the need to reduce these risks among decision-makers, pharmaceutical and healthcare professionals and consumers.

Sikanen has received a number of major awards for her research, including the Award for Scientific Courage from the Academy of Finland in 2019 and the L'Orèal For Women in Science award in 2020. She has published more than 60 scientific articles.

Identifying the signalling mechanisms of cancer cells

Jukka Westermarck is Professor of Cancer Biology at the Department of Medical Biochemistry in the Faculty of Medicine and Research Director at the Turku Bioscience Centre at the University of Turku. He earned the degree of licentiate of medicine in 1996 and a doctorate in medicine with distinction in 1998 from the University of Turku.

His research team has endeavoured to identify the signalling mechanisms in cancer cells that promote malignancy in cancer. The group’s most significant achievement has been the identification of the CIP2A oncoprotein. This has provided new outlooks regarding the future opportunities of cancer treatment. CIP2A overproduction is one of the changes most commonly seen in cancer. “In about 70 per cent of all cancer samples, in almost all cancers, this mechanism is in operation.
Over the last 4 to 5 years, the biology associated with phosphatases has also received attention in drug development. We are now starting to get closer to being able to bring new treatment to patients,” says Westermarck.

Westermarck has received many awards for his successful scientific work, the most significant of which are the Young Investigator Award from the Finnish Medical Society Duodecim in 2007 and the Anders Jahre Young Scientist Award in 2009. He has published 116 original papers and 14 review articles.

Invitation to the award ceremony today, 27 October 2022 (The event will be held in Finnish)

Time: Thursday 27 October 2022 at 15.30 EEST
Place: Biomedicum, hall 3, Haartmaninkatu 8, Helsinki
Click here to join the meeting


Further information:

Anu Imppola
Manager, Orion Research Foundation
Tel. +358 50 966 3803
anu.imppola@orion.fi

Media contacts:

Terhi Ormio
VP, Communications, Orion Corporation
Tel. +358 50 966 4646
terhi.ormio@orion.fi

Published by:
Orion Research Foundation sr